Bergquist Annika, von Seth Erik
Centre for Digestive Diseases, Karolinska University Hospital, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Centre for Digestive Diseases, Karolinska University Hospital, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32. doi: 10.1016/j.bpg.2015.02.003. Epub 2015 Feb 16.
Cholangiocarcinoma (CCA) is a cancer arising from the intra- or extrahepatic bile ducts and mainly characterized by its late diagnosis and fatal outcome. CCA is the second most common primary liver tumour and accounts for approximately 10-15% of all hepatobiliary malignancies. The development of CCA is linked to a wide spectrum of conditions causing biliary inflammation, cholestasis and inflammation of the liver. The geographic diversity of risk factors is reflected in considerable differences in incidence worldwide. Although data are not consistent, incidence seems to be rising in the Western World. Given the limited opportunities of treating advanced CCA, surveillance has been suggested as a strategy for detection of early disease in the high-risk group of patients with primary sclerosing cholangitis (PSC). In this review we present an updated overview of the epidemiology of CCA. We also highlight the risk of CCA in PSC with special focus on surveillance strategies.
胆管癌(CCA)是一种起源于肝内或肝外胆管的癌症,主要特征是诊断较晚且预后不良。CCA是第二常见的原发性肝癌,约占所有肝胆恶性肿瘤的10%-15%。CCA的发生与多种导致胆管炎症、胆汁淤积和肝脏炎症的疾病有关。危险因素的地域差异反映在全球发病率的显著差异上。尽管数据并不一致,但在西方世界,发病率似乎在上升。鉴于治疗晚期CCA的机会有限,有人建议将监测作为在原发性硬化性胆管炎(PSC)高危患者群体中检测早期疾病的策略。在本综述中,我们提供了CCA流行病学的最新概述。我们还强调了PSC患者发生CCA的风险,特别关注监测策略。